Brought to you by 
Bioclassifier licenses breast cancer biomarker to NanoString
16 Dec 2010
Executive Summary
Bioclassifier LLC has granted fellow molecular diagnostics and research firm NanoString Technologies Inc. exclusive worldwide rights to develop new breast cancer tests based on gene expression analysis and intrinsic subtyping.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bioclassifier licenses breast cancer biomarker to NanoString
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice